Study Summary
This trial tests how intranasal oxytocin affects bone health in 6-18yo children with autism over 12mo. Subjects will get oxytocin or placebo and assessments throughout.
- Autism
- Osteoporosis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: 12 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
1. Intranasal Oxytocin
1 of 2
2. Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
96 Total Participants · 2 Treatment Groups
Primary Treatment: 1. Intranasal Oxytocin · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 6 - 18 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does this clinical trial allow persons aged 35 and over to participate?
"This medical trial is targeting people aged 6 to 18. According to the data, there are 423 clinical trials available for minors and 672 studies suited for senior citizens." - Anonymous Online Contributor
Who is eligible to participate in this clinical experiment?
"This clinical trial seeks 96 participants who are between the ages of 6 and 18, as well as being diagnosed with autism." - Anonymous Online Contributor
Is it feasible to participate in this experiment at the present?
"Per clinicaltrials.gov, this particular trial has concluded its recruitment phase and is no longer actively searching for participants as of February 22nd 2023. However, there are 1152 other studies with ongoing enrolment across the world at present." - Anonymous Online Contributor
Has the FDA sanctioned intranasal oxytocin for medical use?
"Our team has assigned an intermediate safety level of 2 to intranasal oxytocin, as the phase two trial data only supports its safety and not efficacy." - Anonymous Online Contributor